Two Deaths Reported to the FDA After “Research Use Only” Reta: How to Tell a Prescription From a Package

What CBS News reported

On October 13, 2026, CBS News published documents it obtained from the FDA under the Freedom of Information Act. They describe two deaths submitted to the FDA Adverse Event Reporting System, both naming products claiming to be retatrutide as a “suspect product.”

• July 2026. A health care professional reported that a 41-year-old woman with obesity, described as otherwise healthy, went into cardiac arrest with a dangerously fast heartbeat and could not be resuscitated. The report says she obtained retatrutide “from an unreliable source” and notes she was drinking kava at the time of the emergency.
• September 2026. A report said a 49-year-old patient died after a licensed registered nurse “convinced” her to buy retatrutide from an online vendor, “provided her the link and sold her vials and provided recommended dosages.” She experienced severe dehydration, malnutrition, and cardiac arrest. The report included a photo of a vial labeled with a “research use only” brand; the company’s attorney told CBS News the image does not match its current packaging and that the redacted report does not establish the product came from them.

Three caveats matter, and CBS News was careful to state them. Adverse event reports are unverified. The FDA declined to say whether it has confirmed either account. And a report listing a “suspect product” is not a finding that the product caused the death. Harvard Medical School’s Pieter Cohen told CBS the FDA “should get their hands on the actual drug that was injected by both of these patients” and have it analyzed.

Those caveats do not make the story less important. They make it a story about a market, not about one vial.

What retatrutide is, and what “research use only” is not

Retatrutide is an investigational drug from Eli Lilly that acts on three hormone receptors (GLP-1, GIP, and glucagon). It is in Phase 3 trials. In July 2026, Lilly reported trial participants with obesity and type 2 diabetes lost an average of 20.8% of body weight at 80 weeks on the highest dose, which is why the drug has a nickname, a fan base, and a black market before it has an approval.

Lilly’s own words, from its August 12 release: “No medicine containing retatrutide has yet been approved for human use by any regulatory authority.” Its chief medical officer: “What is being sold on the black market is not a medicine – it is entirely unverified, unapproved and not worth the risk.” Lilly filed six lawsuits that day against sellers in Texas and California and asked payment processors, shippers, and social platforms to cut them off.

Lilly’s lawsuits name peptide retailers and at least one compounding pharmacy, and the question of whether and how a licensed pharmacy may compound an investigational molecule is now being argued in federal court. That is a legal dispute between a manufacturer and pharmacies, and it is a question for your clinician and the pharmacy’s lawyers, not for a website checkout page.

The “research use only” market is a different thing entirely, and it is what both FDA reports describe. The FDA says it “has warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that are falsely labeled ‘for research purposes’ or ‘not for human consumption.’” No prescriber, no pharmacy, no label, no accountability. Whatever you think about compounding, this is not compounding. It is a package.

“Research use only” is the tell

Every bootleg vial carries the same three words, and they are doing a specific job. “Research use only” is the seller’s statement to regulators that the product is not meant for people. The dosing chart on the same website is the seller’s statement to you that it is. The FDA describes exactly this pattern: “These products have been sold directly to consumers for human use with dosing instructions,” and “the agency urges consumers not to purchase these products which are of unknown quality and may be harmful to their health.”

Behind the label there is no pharmacist, no prescriber, no sterile compounding standard, no lot testing you can see, and no one whose license is on the line if the vial contains the wrong drug or ten times the dose. Lilly says it has found suspect products with “too much, too little, or the wrong active ingredient,” along with contaminants.

A license is not a safeguard if the product is bootleg

The detail in the September report that should stop every reader is not the vial. It is that a licensed nurse reportedly sent the link, sold the vials, and recommended the doses. The vendor’s own attorney said it plainly: “A licensed healthcare professional should never recommend research-use-only products to a patient, provide dosing instructions for them, administer them, or sell them.”

A credential tells you someone passed an exam. It does not tell you what is in the syringe. A legitimate telehealth prescription has a chain you can see at every link: a licensed clinician reviews your history and writes a prescription; a licensed pharmacy fills it; the vial that arrives carries that pharmacy’s name, your name, the drug and strength, a lot number, and a beyond-use date. If any link is missing, the credential at the front of the chain does not protect you.

The same logic applies to certification seals. In September, CBS News found more than 80 businesses promoting retatrutide while displaying a LegitScript certification seal, and at least 35 showed the seal on the same page as the retatrutide offer. LegitScript said the companies were flagged by its monitoring and that its “policy is not to immediately revoke the certification in all instances.” A seal is a starting point for your own checks, not a substitute for them.

The numbers behind the story

“Exposure” in poison-center data means contact with a substance, not a confirmed poisoning. The trend is the point: exposures more than tripled across 2026 for a drug that is not for sale.

Seven checks before you inject anything bought online

1. Is a licensed pharmacy dispensing it under a prescription written for you? If the answer is a website, a “research” disclaimer, or a person with a link, stop here. Everything else on this list assumes the answer is yes.
2. Did a licensed clinician review your history and write a prescription? Not a quiz, not a chat bot, not a “protocol.” A prescription, from a named, licensed clinician, in your name.
3. Is a licensed pharmacy filling it, and will they tell you which one? Ask. A legitimate program will name the pharmacy when you ask, and it will be on the label.
4. What does the label say? Pharmacy name, your name, drug and strength, lot number, beyond-use date. “Research use only” or “not for human consumption” anywhere on the vial ends the conversation.
5. Who gave you the dose? A clinician who can see your chart, or a website chart and a DM? The September report describes the second.
6. Where did the money go? Crypto, Zelle, Venmo, or a payment page with no business name are the payment rails of sellers Lilly is asking processors to cut off.
7. Does the seal match the behavior? A certification badge is worth checking on the certifier’s own site, and worth nothing if the page beside it offers an unapproved drug.

If a program fails any one of these, the price does not matter.

If you have already bought or used “reta”

• Stop using it. There is no safe-use guidance for a product of unknown content.
• Keep the vial, packaging, and any receipts. If you have symptoms, that vial is what a clinician or the FDA needs.
• Call Poison Control at 1-800-222-1222 if you have a racing heart, fainting, severe vomiting or inability to keep fluids down, confusion, or severe abdominal pain. Call 911 for chest pain, collapse, or trouble breathing.
• See a licensed clinician and tell them exactly what you took, how much, and when, even if it is embarrassing. They cannot help with what they do not know.
• Report it to the FDA through MedWatch. Reports like the two in this story are how regulators find out.

Where SkinnyVIP stands

We will never point a patient to a “research use only” vendor, and no one on our team sells vials. Every medication a SkinnyVIP patient receives follows the same chain: a licensed clinician reviews your intake and decides whether to prescribe; a licensed compounding pharmacy fills the prescription under physician supervision; the vial arrives with the pharmacy’s name, your name, the drug and strength, a lot number, and a beyond-use date. Our team will tell you which pharmacy filled it when you ask.

We want to be precise about what compounded medication is and is not. It is not an FDA-approved product; FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed. Prescription is not guaranteed; if a clinician says no, you are refunded in full. That chain, clinician to pharmacy to labeled vial, is the whole difference between a prescription and a package. It is the difference the two FDA reports are about.

If you are shopping for GLP-1 treatment online this month, run the seven checks on every program, including ours. Individual results vary.